Skip to content
PeptideAgent

Clinics in Ohio

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What Ohio law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and verified listings.

Ohio at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified clinics serving Ohio

No verified clinics serving Ohio are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Ohio

Yes. An Ohio resident can obtain FDA approved peptides such as semaglutide and tirzepatide from an Ohio-licensed prescriber, including by telehealth: Ohio Revised Code 4743.09 and State Medical Board rule 4731-37-01 let practitioners use synchronous or asynchronous technology, including for an initial visit, when the in-person standard of care can be met. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy licensed by the State of Ohio Board of Pharmacy. Ohio is among the most specific states on GLP-1s: in July 2025 the Board published compounding FAQs treating copies of semaglutide and tirzepatide as no longer compoundable after the shortages ended. [1] [2] [3] [4] [5] [6] [7] [8] [12]

Compounded GLP-1 access in Ohio

Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient specific needs because the FDA shortage allowances ended in 2025, and the Ohio Board of Pharmacy's July 2025 GLP-1 FAQs reinforce that copies of the approved products are not routinely compoundable in Ohio. Ohio's asynchronous telehealth rule makes app-based prescribing lawful, so the main constraint for Ohio patients is the pharmacy side. [3] [4] [9]

Research use only sellers in Ohio

ORC chapter 4729 restricts the sale and distribution of dangerous drugs to licensed pharmacies, distributors, and prescribers, and the Board reminds licensees to verify that sellers are licensed. Board guidance for prescriber clinics and medical spas (updated December 8, 2025) says any drug labeled for research purposes only is unlawful for a clinic or med spa to possess, even with patient consent, and must be disposed of immediately, with patients advised to stop using it. [1] [5] [10] [11]

Ohio notes on specific peptides

  • Semaglutide: Available branded by prescription, including through synchronous or asynchronous telehealth under ORC 4743.09. The Ohio Board of Pharmacy's July 2025 GLP-1 FAQs and the end of the federal grace period on April 22, 2025 leave compounded semaglutide limited to documented patient specific needs. [2] [4] [9]
  • Tirzepatide: Available branded by prescription. Compounded tirzepatide is limited to the federal patient specific exception since February 18, 2025, and the Ohio Board's GLP-1 FAQs address it directly. [4] [9]
  • Retatrutide: Investigational and not FDA approved. The Ohio Board of Pharmacy's July 17, 2025 GLP-1 guidance states that retatrutide cannot be used in compounding under federal and state law and that licensees found compounding, selling, or administering it may face discipline, including summary suspension. [4] [9]

How to check a clinic in Ohio

  1. Confirm the prescribing clinician's license with the Ohio medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the State of Ohio Board of Pharmacy license lookup. [1] [4] [5] [6] [7] [8] [12]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Ohio. [1] [5] [10] [11]

Common questions in Ohio

Can I get a GLP-1 prescription in Ohio through an asynchronous telehealth app?

Yes, if the prescriber holds an Ohio license and the in-person standard of care can be met. ORC 4743.09 and OAC 4731-37-01 allow synchronous or asynchronous technology, including for initial visits, and non-controlled drugs like semaglutide may be prescribed through telehealth. [2] [3]

All peptide legal questions for Ohio

Sources

  1. [1]State of Ohio Board of Pharmacy
  2. [2]Ohio Revised Code 4743.09, Telehealth services
  3. [3]Ohio Administrative Code 4731-37-01, Telehealth (State Medical Board of Ohio)
  4. [4]State of Ohio Board of Pharmacy: Compounding of GLP-1 drug products in Ohio, guidance and FAQs (issued July 17, 2025)
  5. [5]Ohio Revised Code chapter 4729, Pharmacists; dangerous drugs
  6. [6]Ohio Revised Code 4729.54, Terminal distributor licenses
  7. [7]Ohio Administrative Code 4729:5-8-02, Non-resident pharmacies: licensure
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  10. [10]21 U.S.C. 331, Prohibited acts
  11. [11]Ohio Board of Pharmacy: Ten Common Prescriber Clinic and Medical Spa Violations (updated 12/8/2025)
  12. [12]Ohio Board of Pharmacy: Responsible Person Requirements for Licensure (updated 9/10/2026)